Arthneeti
Latest: Sigachi Industries Ltd Q2 FY27 (Jul–Sep 2026) results →This page is Q1 FY26 (Apr–Jun 2025).All Q1 FY26 results →
S

Sigachi Industries Ltd

Q1 FY26Pharmaceuticals & Biotechnology

Sigachi Industries Q1 FY26 earnings call: Revenue & Margins

Q1 FY26 earnings call: what management said on revenue, margins and capex.

Price₹34
Market cap₹995 Cr
P/E30.6
Updated26 Aug 2026
Read4 min read

The short version

FY26 API revenue is expected to reach around INR 70 crores, growing steadily month-on-month from INR 9 crores in Q1. For FY '26, Sigachi expects around INR70 crores revenue from the API segment with an EBITDA margin of 18-20%.

From Sigachi Industries Ltd's Q1 FY26 earnings-call transcript · updated 26 Aug 2026.

Revenue & Sales Performance

  • FY26 API revenue is expected to reach around INR 70 crores, growing steadily month-on-month from INR 9 crores in Q1.
  • EBITDA margin for API segment projected between 18% to 20%.
  • MCC segment to maintain similar capacity levels (~19,000 MT), with the Hyderabad unit (6,400 MT) being restored post-incident.
  • Partial revenue loss of approx. INR 60 crores from Hyderabad plant in next 6 months, with some recovery from other units (Dahej, Jhagadia).
  • Capacity expansion in CCS facility on track for October 2026 with no significant delays expected.
  • Over 2-3 years, API share in revenue mix expected to increase, possibly reducing MCC’s share from current ~80-85% to around 75%.

2 more points from Sigachi Industries Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Sigachi Industries Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • The insurance amount received is expected to cover the entire capex needed to rebuild the Hyderabad facility, including plant, machinery, and building. (Page 14)
  • Detailed capex estimates are pending full access and assessment of the damaged facility. (Page 14)
  • The company is planning to resume operations at Hyderabad plant within approximately 6 months. (Page 7)
  • Commercialization of the new CCS (Co-Processed Cellulose & Starch) facility at Dahej is progressing steadily and expected to be on track by October 2026. (Page 9)

2 more points from Sigachi Industries Ltd's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Sigachi Industries Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • The company indicated minimal export orders currently in the API segment, with expected revenue of around INR70 crores by FY '26 driven primarily by domestic and Rest of World (ROW) markets.
  • The management expressed strong customer support despite a recent incident, indicating confidence in regaining and maintaining order volumes post-disruption.
  • Discussions with customers are ongoing to manage business continuity and fulfill supply commitments as capacities normalize.

2 more points from Sigachi Industries Ltd's call on order book

Create a free account to keep reading this call

Sigachi Industries Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹113 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Sigachi Indust.'s management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • RPG LifeScience. (Q1 FY26)

    168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • SMS Pharma. (Q1 FY26)

    Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…

  • Morepen Labs. (Q1 FY26)

    Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

  • NGL Fine Chem (Q1 FY26)

    Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Sigachi Industries Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Sigachi Industries Ltd Q1 FY26 results?

FY26 API revenue is expected to reach around INR 70 crores, growing steadily month-on-month from INR 9 crores in Q1. For FY '26, Sigachi expects around INR70 crores revenue from the API segment with an EBITDA margin of 18-20%.

What is Sigachi Industries Ltd share price analysis?

Sigachi Industries Ltd currently shows a neutral. The stock trades at a P/E of 30.6 with a market cap of ₹995 Cr. Investors should review the full earnings analysis for detailed insights.

Is Sigachi Industries Ltd planning capital expenditure?

The insurance amount received is expected to cover the entire capex needed to rebuild the Hyderabad facility, including plant, machinery, and building.

Keep Sigachi Industries Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.